What the trials, the labels and the FDA communications state about compounded formulary compounds

Compound evidence: what the trials, reviews, product labels and FDA communications state about the compounds a 503A pharmacy partner prepares for licensed practices, from sermorelin and NAD+ to glutathione, low dose naltrexone, methylene blue, SNAP-8, topical anesthetics and IV nutrient formulations.

Every page reports its sources as written and leaves the prescribing decision to the practitioner.

The references, in reading order

8 references, each with numbered citations to the trials, labels and agency documents.

Repurposed small molecules

The published trials and systematic reviews for low dose naltrexone, and the pharmacology, the approved label and the human studies for methylene blue.

Image credits

  1. Sermorelin: Approval History and TrialsRCSB Protein Data Bank, RCSB PDB, CC0 1.0. PDB 7CZ5, Growth hormone-releasing hormone receptor. Zhou F, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020. ↩
  2. NAD+ and Its Precursors: Human TrialsNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 5892, NAD+ ↩
  3. Glutathione: Oral, IV and Topical EvidenceNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 124886, Glutathione ↩
  4. Low Dose Naltrexone: Trials, Reviews and LabelsNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 5360515, Naltrexone ↩
  5. Methylene Blue: Pharmacology and Human DataNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 6099, Methylene blue ↩
  6. SNAP-8 and Acetyl Hexapeptide-8: StudiesExaVeyra Sciences, original figure. Drawn from Acetyl octapeptide-3 (SNAP-8), drawn by ExaVeyra Sciences with RDKit from the INCI sequence. Original drawing by ExaVeyra Sciences, made with RDKit (open source, BSD license) from the INCI sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. The linked PubChem record (CID 71587832) shows a structure and formula (C42H72N16O15S) that differ from this sequence. ↩
  7. Topical Anesthetics: Pharmacology and AlertsNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 3676, Lidocaine ↩
  8. IV Nutrient Formulations: What Trials ReportNational Center for Biotechnology Information, PubChem, Public domain. PubChem CID 54670067, Ascorbic acid ↩

This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. These references report what trials, reviews, product labels and FDA communications state about compounds that a 503A pharmacy partner prepares, for professional education, and make no statement about the suitability of any product for any patient. Where this page discusses an FDA-approved product, the approved labeling governs and nothing here modifies it. Compounded preparations are a separate product class: they are not FDA-approved finished drug products, they are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a patient-specific prescription, and they are prescription products supplied to licensed practitioners only. Cosmetic ingredients discussed here are described within the cosmetic regulatory frame and are not drugs. The prescribing decision rests with the licensed practitioner.